On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65. It hit its 52-week high of $259.99 and was a ~35% growth from its 52-week low of $191.53 on September 21, 2017.
Becton Dickinson announced quarterly dividend
On July 24, Becton Dickinson’s board of directors announced a dividend of $0.75 per common share, which is expected to be paid on September 28 to shareholders of record on September 7.
Becton Dickinson raised its financial guidance
Becton Dickinson raised its financial guidance after delivering a strong performance in the fiscal third quarter. It anticipates YoY (year-over-year) growth of ~31.5%. Previously, it estimated growth of 31%–31.5%.
Becton Dickinson narrowed its 2018 diluted EPS estimate from $10.90–$11.05 to $10.95–$11.05 after the fiscal third quarter. Its updated earnings demonstrate a 15.5%–16.5% YoY growth in diluted EPS. Becton Dickinson anticipates that on a currency-neutral basis, the company could see a ~12% YoY growth in adjusted diluted EPS.
Of the 18 analysts tracking Becton Dickinson in August, eight of them have recommended a “strong buy,” and five have recommended a “buy.” Five analysts have recommended a “hold.”
On August 29, Becton Dickinson had a consensus 12-month target price of $267.13, which represents a ~3.15% return on investment over the next 12 months.
Of the 25 analysts tracking Medtronic (MDT) in August, ~52% of them have recommended a “buy.” Of the 24 analysts tracking Boston Scientific (BSX) in August, ~58% of them have recommended a “buy.” Of the 19 analysts tracking Abbott Laboratories (ABT) in August, ~79% of them have recommended a “buy.”
On August 29, Medtronic, Boston Scientific, and Abbott Laboratories had consensus 12-month target prices of $102.40, $38.32, and $71.13, respectively, which represent ~6.19%, ~7.84%, and ~6.01% returns on investment, respectively, over the next 12 months.